secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001193125-24-046891
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Biosciences amends severance plan; CEO gets 12-month base, 24-month on change of control
--------------------------------------------------------------------------------

- Compensation Committee approved Second Amended and Restated Severance Benefit Plan effective Feb 20, 2024.
- Non-CIC termination: CEO receives 12 months base salary + COBRA; other NEOs get 9 months base + COBRA.
- CIC termination: CEO receives 24 months base salary + 100% target bonus + 24 months COBRA + full equity vesting.
- Other NEOs get 18 months base salary + 100% target bonus + 18 months COBRA + full equity vesting.
- Benefits require signed release and compliance with restrictive covenants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312524046891/0001193125-24-046891-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312524046891/d755593d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-046891

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer